Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.

Persons

Aaron Seth Kesselheim

Venue / Journal

Health Policy

Date

Thu, 08/01/2019 - 12:00

Additional Journal Information

123(8):721-727

Authors

Vokinger KN, Kesselheim AS.

Pubmed URL

http://www.ncbi.nlm.nih.gov/pubmed/31229275